Vigil Neuroscience study for Alzheimer’s drug to proceed with FDA restrictions (VIGL)

Iryna Drozd

Vigil Neuroscience (NASDAQ:VIGL) said the FDA is allowing a Phase 1 clinical trial for its Alzheimer’s drug candidate VG-3927 to proceed with a partial clinical hold related to the maximum drug exposure limit.

Vigil said it expects to begin dosing

Source link